Insulin resistance and insulin secretion in non-diabetic acromegalic patients

Experimental and Clinical Endocrinology and Diabetes

Volumn 115, Issue 5, 2007, Pages 308-316

  Coculescu, M ^a,b   Niculescu, D ^a,b   Lichiardopol, R ^a,c   Purice, M ^b  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b C I PARHON NATIONAL INSTITUTE OF ENDOCRINOLOGY   (Romania)

^c Nutrition and Metabolic Diseases 'N Paulescu'   (Romania)

Author keywords

Acromegaly; Growth hormone; Insulin resistance

Indexed keywords

GLUCOSE; GROWTH HORMONE; INSULIN; LEVOTHYROXINE; PREDNISONE; TESTOSTERONE UNDECANOATE;

ACROMEGALY; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE SECRETING ADENOMA; HOSPITALIZATION; HUMAN; IMMUNORADIOMETRIC ASSAY; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; REGRESSION ANALYSIS; SENSITIVITY AND SPECIFICITY;

EID: 34249944929     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-961797     Document Type: Article

References (38)

1. Adams KF, Schatzkin A, Harris TB, Kipnis V, Mouw T, Ballard-Barbash R, Hollenbeck A, Leitzmann MF: Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med 2006; 355 (8):763-778
2. Ayuk J, Clayton RJV, Holder C, Sheppard MC, Stewart PM, Bates AS: Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 2004; 89 (4):1613-1617
3. Baldelli R, Battista C, Leonetti F, Ghiggi MR, Ribaudo MC, Paoloni A, D'Amico E, Ferretti E, Baratta R, Liuzzi A, Trischitta V, Tamburrano G: Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment. Clin Endocrinol (Oxf) 2003; 59 (4): 492-499
4. Barkan AL, Burman P, Clemmons DR, Drake WM, Gagel RF, Harris PE, Trainer PJ, van der Lely AJ, Vance ML: Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab 2005; 90 (10):5684-5691
5. Bates AS, Van't Hoff W, Jones J: Does treatment of acromegaly affect life expectancy? Metabolism 1995; 44 (suplement 1):1-5
6. Biering H, Knappe G, Gerl H, Lochs H: [Prevalence of diabetes in acromegaly and Cushing syndrome]. Acta Med Austriaca 2000; 27 (1):27-31
7. Biermasz NR, Dekker FW, Pereira AM, van Thiel SW, Schutte PJ, van Dulken H, Romijn JA, Roelfsema F: Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. J Clin Endocrinol Metab 2004; 89 (6):2789-2796
8. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monauni T, Muggeo M: Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000; 23 (1):57-63
9. Cappiello V, Ronchi C, Morpurgo PS, Epaminonda P, Arosio M, Beck-Peccoz P, Spada A: Circulating ghrelin levels in basal conditions and during glucose tolerance test in acromegalic patients. Eur J Endocrinol 2002; 147 (2):189-194
10. Christy NP: Choosing the best treatment for acromegaly. JAMA 1982; 247(9):1320
11. Colao A, Ferone D, Marzullo P, Lombardi G: Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004; 25 (1):102-152
12. Cozzi R, Montini M, Attanasio R, Albizzi M, Lasio G, Lodrini S, Doneda P. Cortesi L, Pagani G: Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 2006; 91 (4):1397-1403
13. Dimaraki EV, Jaffe CA, DeMott-Friberg R, Chandler WE, Barkan AL: Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. J Clin Endocrinol Metab 2002; 87 (8): 3537-3542
14. Emoto M, Nishizawa Y, Maekawa K, Hiura Y, Kanda H, Kawagishi T, Shoji T, Okuno Y, Morii H: Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Diabetes Care 1999; 22 (5):818-822
15. Firth SM, Baxter RC: Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002; 23 (6):824-854
16. Flier JS, Usher P, Moses AC: Monoclonal antibody to the type I insulin-like growth factor (IGF-I) receptor blocks IGF-I receptor-mediated DNA synthesis: clarification of the mitogenic mechanisms of IGF-I and insulin in human skin fibroblasts. Proc Natl Acad Sci USA 1986; 83 (3):664-668
17. Foss MC, Saad MJ, Paccola GM, Paula FJ, Piccinato CE, Moreira AC: Peripheral glucose metabolism in acromegaly. J Clin Endocrinol Metab 1991; 72 (5):1048-1053
18. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S: Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000; 85 (2):526-529
19. Guler HP, Zapf J, Froesch ER: Short-term metabolic effects of recombinant human insulin-like growth factor 1 in healthy adults. N Engl J Med 1987; 317 (3):137-140
20. Hansen I, Tsalikian E, Beaufrere B, Gerich J, Haymond M, Rizza R: Insulin resistance in acromegaly; defects in both hepatic and extrahepatic insulin action. Am J Physiol 1986; 250 (3 Pt 1):E269-E273
21. Holdaway IM, Rajasoorya CR, Gamble GD, Stewart AW: Long-term treatment outcome in acromegaly. Growth Horm IGF Res 2003; 13 (4):185-192
22. Holdaway IM, Rajasoorya RC, Gamble GD: Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004; 89 (2):667-674
23. Jasper H, Pennisi P, Vitale M, Mella A, Ropelato G, Chervin A: Evaluation of disease activity by IGF-I and IGF binding protein-3 (IGFBP3) in acromegaly patients distributed according to a clinical score. J Endocrinol Invest 1999; 22 (1):29-34
24. Kalloo-Hosein HE, Whitehead JP, Soos JM, Tavare JM, Siddle K, O'Rahilly S: Differential signaling to glycogen synthesis by the intracellular domain of the insulin versus the insulin-like growth factor-1 receptor. Evidence from studies of TrkC-chimeras. J Biol Chem 1997; 272 (39):24325-24332
25. Kasayama S, Otsuki M, Takagi M, Saito H, Sumitani S, Kouhara H, Koga M, Saitoh Y, Ohnishi T, Arita N: Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol (Oxf) 2000; 52 (5):549-555
26. Kreze A, Kreze-Spirova E, Mikulecky M: Risk factors for glucose intolerance in active acromegaly. Braz J Med Biol Res 2001; 34 (11):1429-1433
27. Luft R, Cerasi E, Hamberger CA: Studies on the pathogenesis of diabetes in acromegaly. Acta Endocrinol (Copenh) 1967; 56 (4):593-607
28. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28 (7):412-419
29. Melmed S: Acromegaly. In: DeGroot L, Jameson J, editors. Endocrinology. 5th ed. Philadelphia: Elsevier Saunders, 2006, p 411-428
30. Mestron A, Webb SM, Astorga R, Benito P, Catala M, Gaztambide S, Gomez JM, Halperin I, Lucas-Morante T, Moreno B, Obiols G, de Pablos P, Paramo C, Pico A, Torres E, Varela C, Vazquez JA, Zamora J, Albareda M, Gilabert M: Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol 2004; 151 (4):439-446
31. Miyakawa M, Tsushima T, Murakami H, Isozaki O, Demura H, Tanaka T: Effect of growth hormone (GH) on serum concentrations of leptin: study in patients with acromegaly and GH deficiency. J Clin Endocrinol Metab 1998; 83 (10):3476-3479
32. Moller N, Schmitz O, Joorgensen JO, Astrup J, Bak JF, Christensen SE. Alberti KG, Weeke J: Basal- and insulin-stimulated substrate metabolism in patients with active acromegaly before and after adenomectomy. J Clin Endocrinol Metab 1992; 74 (5):1012-1019
33. Poggi C, Marchand-Brustel Y, Zapf J, Froesch ER, Freychet P: Effects and binding of insulin-like growth factor 1 in the isolated soleus muscle of lean and obese mice: comparison with insulin. Endocrinology 1979; 105 (3):723-730
34. Puder JJ, Nilavar S, Post KD, Freda PU: Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly. J Clin Endocrinol Metab 2005; 90 (4):1972-1978
35. Serri O, Beauregard C, Hardy J: Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly. J Clin Endocrinol Metab 2004; 89 (2):658-661
36. Trainer PJ: Editorial: acromegaly - consensus, what consensus? J Clin Endocrinol Metab 2002; 87 (8):3534-3536
37. World Health Organisation 1999, Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications Report of a World Health Organisation Consultation, Part 1: Diagnosis and Classification of Diabetes Mellitus. Available from.
38. Yeni-Komshian H, Carantoni M, Abbasi F, Reaven GM: Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers. Diabetes Care 2000; 23 (2):171-175